The $35 billion race to cure a silent killer that affects 30 million Americans

At the Mayo Clinic in Jacksonville, Florida, the liver transplant group is busy handling an onslaught of patients who have come from all over the country in hopes of a chance at life. For many, a liver transplant is their last hope, after being diagnosed with a deadly disease sweeping …

Are These Red-Hot NASH Stocks Still a Buy?

Over the last two weeks, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL), Galmed Pharmaceuticals (NASDAQ: GLMD), and Viking Therapeutics (NASDAQ: VKTX) have more than doubled in value. The reason? Each of these companies is developing a drug for a deadly form of fatty liver disease known as non-alcoholic steatohepatitis (NASH). The …